Appeal No. 95-4824
Application 07/966,163
OPINION
We have carefully considered all of the arguments advanced
by appellants and the examiner and agree with appellants that the
aforementioned rejections are not well founded. Accordingly,
these rejections will be reversed.
Coveney discloses bismuth-containing pharmaceutical
compositions which are suitable for oral administration and which
coat the gastrointestinal tract (col. 1, lines 59-63). The
compositions include from about 0.1% to about 50% of a
pharmaceutically-acceptable bismuth-containing agent, from about
0.1% to about 25% of a pharmaceutically acceptable non-ionic
cellulose ether polymer, and from about 0.1% to about 25% of
magnesium aluminum silicate, wherein the ratio of bismuth to non-
ionic cellulose ether polymer is greater than about 1.5:1 (col.
1, line 63 - col. 2, line 3). The compositions are useful for
treating or preventing disturbances of the gastrointestinal
tract, such as diarrhea, nausea, heartburn, indigestion, upset
stomach, gastritis and ulcers (col. 2, lines 6-8; col. 6, lines
10-30).
-3-3
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007